Covista (CVSA) Earnings Date & Reports

Key Takeaways

• Revenue reached $511.5 million, up 10.7% year over year and above the roughly $489 million consensus estimate.
• Adjusted earnings per share (EPS) came in at $2.19, comfortably ahead of the consensus estimate of about $1.83.
• Total enrollment rose 7.6% to 104,713 students, marking a 13th consecutive quarter of enrollment growth.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) climbed 17.1% to $131.2 million, with margin expanding to 25.6%.
• Management raised its full-year fiscal 2027 guidance for both revenue and adjusted EPS on the strength of the quarter.
• Shares edged higher in the immediate aftermath of the release as investors digested the beat-and-raise report.
• For more detail on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages.
• Discover Trending AI Robots to see how AI-driven trading strategies are identifying opportunities across the market.

Earnings Context and Why It Matters

Covista Inc., America's largest healthcare educator, operates institutions including Chamberlain University, Walden University, and the Ross University schools across nursing, medicine, and veterinary disciplines. The company's fiscal year runs from July through June, meaning this report covers the first quarter of fiscal 2027, the three months ended in September 2026. Because enrollment trends drive future revenue, investors closely watch student counts alongside profitability. The quarter tested whether Covista's multi-year expansion could continue amid changes to federal student loan programs, which shifted some enrollment timing between intake cycles. Strong results here signal durable demand for healthcare education and support the company's "Purpose at Scale" growth strategy.

Reported Results

Covista reported first quarter fiscal 2027 revenue of $511.5 million, a 10.7% increase from the prior-year period and above Wall Street's consensus estimate of approximately $489.4 million. Growth was broad-based across all three segments, led by Walden and the Medical and Veterinary businesses, with Chamberlain contributing even as it invests in new campuses.

Adjusted EPS was $2.19, up 25.1% year over year and well above the consensus estimate of roughly $1.83. On a GAAP (generally accepted accounting principles) basis, net income was $67.4 million, or $1.95 per share. Adjusted net income rose 16.8% to $75.8 million, supported by a lower share count and reduced interest expense. Adjusted EBITDA increased 17.1% to $131.2 million, with an adjusted EBITDA margin of 25.6%, up 140 basis points from the prior year.

Total company enrollment grew 7.6% to 104,713 students. Management raised full-year fiscal 2027 revenue guidance to a range of $2.06 billion to $2.09 billion, up from a prior midpoint of $2.07 billion, and lifted adjusted EPS guidance to a range of $9.00 to $9.20, roughly $9.10 at the midpoint. One area to note: free cash flow margin came in at 14.9%, down from 24.8% a year earlier, reflecting continued investment in growth initiatives.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking companies like Covista across the education and healthcare services space, the AI Screener offers a streamlined way to surface actionable candidates.

Market Reaction and Investor Sentiment

Shares of Covista edged higher by roughly 1.2% in the immediate aftermath of the release, reflecting a broadly positive but measured response to a quarter that topped both revenue and profit expectations while raising full-year guidance. The muted magnitude of the move suggests investors had already priced in much of the company's momentum, though the enrollment durability and margin expansion offered reassurance about the quality of growth. Sentiment heading into the report had been supported by a streak of estimate beats, and the confirmation of a 13th consecutive quarter of enrollment growth reinforced confidence in the underlying demand story, even as attention turned to the modest decline in free cash flow margin.

Forward Outlook and Key Factors to Monitor

Following the beat-and-raise quarter, investors will likely focus on whether Covista can sustain its enrollment trajectory through the remainder of fiscal 2027. Management noted that some students accelerated their start dates ahead of changes to federal loan programs, which shifted timing between the May and September intake cycles. As a result, the company emphasized that the two periods should be viewed together, and investors will be watching to confirm the blended trend remains healthy.

Margin expansion will be another key theme. The adjusted EBITDA margin improved 140 basis points, but free cash flow margin declined as the company funds strategic initiatives, including new Chamberlain campuses and enterprise technology investments such as an AI-powered classroom. Monitoring how these investments translate into enrollment efficiency and long-term profitability will be central to the narrative.

Partnerships with health systems such as Advocate Health and SSM Health also represent a growth lever, offering a more durable enrollment pipeline at a lower cost of acquisition. Finally, regulatory and policy developments around federal student loans and healthcare education funding remain important external factors that could influence student demand and, in turn, revenue and earnings over the coming quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations